|牛磺猪去氧胆酸钠盐水合物|CsnPharm

CAS No.: 110026-03-4

Taurodeoxycholic acid sodium hydrate Catalog No. CSN27386

Synonyms: Sodium taurodeoxycholate monohydrate;牛磺脱氧胆酸钠水合物

Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate) prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid sodium hydrate is investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Taurodeoxycholic acid sodium hydrate (TUDCA) prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid sodium hydrate is investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis. TUDCA abolished TG-induced markers of ER stress; reduced calcium efflux, induction of Bip/GRP78, and caspase-12 activation; and subsequently inhibited activation of effector caspases and apoptosis. Mitochondria play a secondary role in ER-mediated apoptosis and that TUDCA prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation^[3]. Treatment with tauroursodeoxycholic acid (TUDCA), a hydrophilic bile acid, prevented neuropathology and associated behavioral deficits in the 3-nitropropionic acid rat model of HD (Huntington's disease). Systemically administered TUDCA led to a significant reduction in striatal neuropathology of the R6/2 transgenic HD mouse. R6/2 mice began receiving TUDCA at 6 weeks of age and exhibited reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions. Moreover, locomotor and sensorimotor deficits were significantly improved in the TUDCA-treated mice^[4]. TUDCA reduces the damaging effects of TDCA (taurodeoxycholic acid) on fundus gastric mucosa; TUDCA may play an important role in the treatment of gastritis associated with bile reflux^[5].
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.8529 mL
- 9.2644 mL
- 18.5288 mL
- 5 mM
- 0.3706 mL
- 1.8529 mL
- 3.7058 mL
- 10 mM
- 0.1853 mL
- 0.9264 mL
- 1.8529 mL

技术信息

CAS号

110026-03-4

储存条件

粉末: Keep in dark place,Inert atmosphere,Room temperature

液体: -20°C:3-6 月 -80°C:12月

分子式

C26H46NNaO7S

运输

蓝冰

分子量

539.70

别名

Sodium taurodeoxycholate monohydrate;牛磺脱氧胆酸钠水合物

溶解度

DMSO	120.0 mg/mL (222.3 mM) warming

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Taurodeoxycholic acid sodium hydrate Catalog No. CSN27386

靶点选择性

请登录您的专属账户

确认信息